NJOY Expands Senior Management Team
Appoints chief scientist and international regulatory affairs executive
Published in CSP Daily News
SCOTTSDALE, Ariz. -- NJOY, America’s No. 1 independent electronic cigarette company, announced the addition of two members to the company’s senior leadership team, adding Dr. Joshua Rabinowitz as chief scientist and David Graham as senior vice president for international regulatory affairs.
The addition of these highly respected and experienced executives to oversee the company’s scientific research and international regulatory affairs reflects the commitment of NJOY to leadership in obsoleting tobacco cigarette smoking worldwide.
Dr. Rabinowitz, currently serving as a consultant, will join NJOY full time effective Feb. 1, 2014. Rabinowitz is responsible for all science-related aspects of the business, including the laboratory and clinical testing of NJOY products, and oversight of product manufacturing and quality control. He will work closely with former U.S. Surgeon General Dr. Richard Carmona, the head of NJOY’s Scientific Advisory Committee.
Rabinowitz comes to NJOY on a leave of absence from Princeton University, where he is a full professor in the Department of Chemistry and the Lewis-Sigler Institute for Integrative Genomics. Rabinowitz received both an M.D. and Ph.D. from Stanford University. Thereafter, he co-founded Alexza Pharmaceuticals, where he invented the Adasuve Inhaler for treatment of acute agitation, an FDA-approved inhalation drug product. Rabinowitz is an inventor of more than 130 U.S. patents and author of more than 110 major journal articles, including seven in the past four years in Science or Nature.
Graham, in a newly created position, will oversee all regulatory affairs in the U.S. and abroad. Graham was previously senior director of international government affairs at Johnson & Johnson, where he led tobacco control-related public policy for key markets around the globe. Before joining Johnson & Johnson, he was senior director of global public policy for Pfizer, where he led public policy for their Tobacco Dependence business. Graham is a graduate of Columbia University School of International & Public Affairs with a Masters in Public Policy & Administration. He has more than 20 years of experience with tobacco control, smoking cessation and related regulatory reforms.
“NJOY is committed to the scientific understanding of our products and advancing research of the e-cigarette industry. Recruiting individuals of this caliber is a testament to our early success, our gold-standard practices and above all our full commitment to our mission--to obsolete cigarettes,” said Craig Weiss, CEO of NJOY. “Dr. Rabinowitz’s and Mr. Graham’s expertise will be critical as we look to improve further our products, ensure cohesive and effective regulation in the category, and raise awareness about e-cigarettes as a viable alternative for adult tobacco consumers not just in the U.S. but globally.”
NJOY is known as the industry's gold standard for its product quality, patented technology and responsible marketing. The company has a demonstrated commitment to advancing research and scientific understanding of electronic cigarettes and appointed former Surgeon General Dr. Richard Carmona to its Board of Directors and Scientific Advisory Committee in March 2013.
NJOY is currently in over 80,000 stores in the U.S. and more than 10,000 across the UK, France, Spain, Italy, Portugal and the Netherlands. NJOY is headquartered in Scottsdale, Ariz., and has offices in New York and London.